Search

Your search keyword '"Jaeger, Bernadette"' showing total 96 results

Search Constraints

Start Over You searched for: Author "Jaeger, Bernadette" Remove constraint Author: "Jaeger, Bernadette"
96 results on '"Jaeger, Bernadette"'

Search Results

2. Impact of surgical variables on residual glandular tissue in risk-reducing mastectomies: Results of a retrospective monocentric study from a center of the German consortium for hereditary breast and ovarian cancer

4. Determination of the androgen receptor status of disseminated tumor cells in primary breast cancer patients

5. Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells—Results From the SUCCESS A Trial

6. Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study

7. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer

8. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial.

10. Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast or Advanced Gynecological Cancer -A Feasibility Study-

12. Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients

13. Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis

14. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

15. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

17. Position Paper: Appropriate Use of Pharmacotherapeutic Agents by the Orofacial Pain Dentist.

18. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer

19. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer

20. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial

22. A novel approach to assess Her2-status of circulating tumour cells (CTCs) using the automated BioMarQ System.

23. Abstract P4-01-08: Persistence of circulating tumor cells immediately after and two years after systemic adjuvant chemotherapy in patients with early breast cancer – Results of the German SUCCESS trials

24. Abstract OT1-2-03: The DETECT-study concept: Treatment based on the phenotype of circulating tumor cells in HER2-negative metastatic breast cancer

25. DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor cells (CTCs).

26. Discordance of the ER- and HER2-status on disseminated tumor cells (DTCs) compared to the primary tumor (PT) in patients with early breast cancer (BC).

27. Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study.

28. Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC).

29. Biomarq: A novel approach to automated HER2-analysis of circulating tumor cells (CTCs).

30. Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial.

31. Measuring the course of anxiety in women giving birth by caesarean section: a prospective study.

32. HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.

33. Correlation of BMI with tumor stage in early breast cancer patients (pts): Pooled analysis of the German SUCCESS A, B, and C trials.

34. DETECT III: A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients (pts) with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells (CTC).

36. Prevalence of myofascial pain in general internal medicine practice

37. CHAPTER 11: NON-ODONTOGENIC TOOTHACHE AND CHRONIC HEAD AND NECK PAIN.

38. Chapter 8: NONODONTOGENIC TOOTHACHE AND CHRONIC HEAD AND NECK PAINS.

39. Application of Psychometric Testing for Validation in the Field of Orofacial Pain.

40. Myofascial trigger point pain.

45. Are “Cervicogenic” Headaches Due to Myofascial Pain and Cervical Spine Dysfunction?

46. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

47. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Catalog

Books, media, physical & digital resources